Pharmacia & Upjohn adds 600 reps
KALAMAZOO, MI - Pharmacia & Upjohn is expanding its prescription pharmaceutical sales force by more than 600 sales representatives and sales managers.
KALAMAZOO, MI - Pharmacia & Upjohn is expanding its prescription pharmaceutical sales force by more than 600 sales representatives and sales managers.
Currently, the company employs more than 1,300 salespeople. With its aggressive new hiring, anticipated to be complete by mid-1998, Pharmacia & Upjohn will have a sales force with numbers pushing 2,000.
The majority of new hires will join the existing primary care force, according to Greg Schofield, the company's vice president of U.S. sales. Those representatives will be responsible for promoting Caverject, Estring, Depo-Provera, Luvox and Vantin, as well as new products Pharmacia & Upjohn plans to promote heavily in 1998, such as Camptosar, Mirapex, Xalatan and Destrusitol, a urinary incontinence product awaiting FDA approval.
"We're going from one primary sales force to two," Schofield said. "One will have a specialty focus on neurology and urology, and the other will handle a women's health and central nervous system product line."
Ten salespeople will be hired as district managers, approximately 120 new hires will join the company's institutional sales force to promote strictly hospital-based products and an undisclosed number of field representatives will fill out the ranks of existing specialty forces that market oncology, ophthalmology, peptide hormone and HIV/AIDS product lines. All field reps will promote new products.
Pharmacia & Upjohn made its recruiting announcement less than one month after it unveiled a plan to relocate its corporate headquarters from Kalamazoo, MI to an undetermined site in the mid-Atlantic region.
Although sales representatives will be hired to cover territories in every major U.S. city, Schofield believes the company's decision to move headquarters from Kalamazoo to the East Coast will facilitate hiring.
"It's much easier to attract talent to a bigger metropolitan area like the New York/New Jersey area. We're in a dynamic, competitive marketplace and we're looking for dynamic, competitive sales professionals to lead the way." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
